AGP Executive Report
Last update: 4 hours agoClinical Research: A two-year observational study of 3,744 chronic-pain patients linked medical cannabis treatment with improvements in pain, sleep, anxiety and quality of life, though it cannot prove cannabis caused the gains. Consumer Safety: A Colorado audit found major gaps in cannabis testing and oversight; nearly three-quarters of marijuana processed for sale from 2023 to 2025 was not tested for pesticides. CBD Business: York-based HempWell secured multi-million-pound investment to expand production, including a gummy line, and enter adjacent health markets. Regulation: A Kentucky cannabis-company founder warns looming federal hemp restrictions could threaten full-spectrum CBD oils, adding uncertainty for businesses and consumers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.